Product Description

BRCA2 Monoclonal Antibody

Catalogue Numbers: MB67012-50, MB67012-100

Sizes: 50µl, 100µl

Product: Mouse IgG1 kappa. Liquid in PBS, pH 7.3, 30% glycerol, and 0.01% sodium azide.

Swiss-Prot: P51587

Host: Mouse

Reactivity: Human

Applications: WB

All Applications: WB (1/500 - 1/1000)

Background: The breast cancer susceptibility proteins BRCA1 and BRCA2 are frequently mutated in cases of hereditary breast and ovarian cancers and have roles in multiple processes related to DNA damage, repair, cell cycle progression, transcription, ubiquitination, and apoptosis . BRCA2 has been shown to be required for localization of Rad51 to sites of double stranded breaks (DSBs) in DNA, and cells lacking BRCA1 and BRCA2 cannot repair DSBs through the Rad51-dependent process of homologous recombination (HR) . Numerous DNA damage-induced phosphorylation sites on BRCA1 have been identified, including Ser988, 1189, 1387, 1423, 1457, 1524, and 1542, and kinases activated in a cell cycle-dependent manner, including Aurora A and CDK2, can also phosphorylate BRCA1 at Ser308 and Ser1497, respectively . Cell cycle-dependent phosphorylation of BRCA2 at Ser3291 by CDKs has been proposed as a mechanism to switch off HR as cells progress beyond S-phase by blocking the carboxy terminal Rad51 binding site .

Purification and Purity: This antibody is purified through a protein G column.

Storage and Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: Recognizes endogenous levels of BRCA2 protein.

Extra Notes: Western blot analysis of BRCA2 expression in recombinant protein (A) whole cell lysates.

Bioworld Molecular Weight: ~ 380 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Name: FACD; FANCD1; Breast cancer type 2 susceptibility protein; Fanconi anemia group D1 protein

Immunogen: Recombinant fusion protein of human BRCA2. The exact sequence is proprietary.

Conjugate: Unconjugated

Modification: Unmodified